All new pharmaceuticals with Marketing Authorisation are subject to a single technology assessment (STA) before they can be funded by the public sector - either by the hospitals or under the National Insurance Scheme (“folketrygden”).
Pharmaceutical companies prepare documentation at the request of the Norwegian Medicines Agency. The documentation is submitted by e-mail to:firstname.lastname@example.org, with a copy to either email@example.com (for pharmaceuticals to be funded by the "folketrygden") or firstname.lastname@example.org (for pharmaceuticals to be funded by the hospitals). It is important to include the following information in the e-mail text: Brand name/trade name, Active substance, and Nordic package number covered by the documentation.
The Norwegian Medicines Agency has prepared guidelines for the duty of confidentiality (STA) under the existing legislation .